Previous close | 0.4550 |
Open | 0.4600 |
Bid | 0.3220 x 200 |
Ask | 0.5946 x 200 |
Day's range | 0.4551 - 0.4698 |
52-week range | 0.2570 - 3.2800 |
Volume | |
Avg. volume | 480,250 |
Market cap | 14.748M |
Beta (5Y monthly) | 3.45 |
PE ratio (TTM) | 0.12 |
EPS (TTM) | 4.0000 |
Earnings date | 10 June 2024 - 14 June 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 760.00 |
Residents in a retirement village will have their council tax cut after winning a 16-year-long battle over incorrect bills.
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as a therapyg for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) from the Chinese National Intellectual Property Administration (CNIPA), valid through 2035 (Chinese Patent Application No.: 202110229970.9 issued April 29, 2024).
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment. RHB-107 (upamostat) is the first drug being tested in this platform study. Funded through non-dilutive external sources, including the U.S. Department of D